Price Alert

Anixa Biosciences Inc. (ANIX)

NASDAQ: ANIX · Real-Time Price · USD

3.34

-0.04 (-1.04%)

At close: Sep 26, 2025, 10:59 AM

-1.04% (1D)

Bid	2.43
Market Cap	109.93M
Revenue (ttm)	n/a
Net Income (ttm)	-8.86M
EPS (ttm)	-0.34
PE Ratio (ttm)	-9.82
Forward PE	-9.83
Analyst	Buy
Dividends	n/a

Ask	4.33
Volume	43,162
Avg. Volume (20D)	105,707
Open	3.38
Previous Close	3.38
Day's Range	3.33 - 3.44
52-Week Range	2.07 - 4.20
Beta	0.59
Ex-Dividend Date	n/a

About ANIX

undefined

[Read more]

Industry n/a

Sector n/a

IPO Date n/a

Employees NaN

Stock Exchange n/a

Ticker Symbol ANIX

Website n/a

Full Company Profile

Analyst Forecast

According to 0 analyst ratings, the average rating for ANIX stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.

Stock Forecasts

Why Price Moved

3 months ago

+23.19%

Anixa Biosciences shares are trading higher after ... Unlock content with Pro Subscription

3 months ago

+12.45%

Anixa Biosciences shares are trading higher after the company announced it completed enrollment for its Phase 1 breast cancer vaccine clinical trial.

News

2 weeks ago · marketbeat.com

3 Under-the-Radar Biotechs Under $5 That Could Soar 200%

Investing in biotechnology stocks is typically reserved for speculative investors. For starters, many of these companies are clinical or pre-clinical stage companies.

2 months ago · zacks.com

Is Anixa Biosciences (ANIX) Stock Outpacing Its Medical Peers This Year?

Here is how ANIXA BIOSCIENCES INC (ANIX) and Mind Medicine (MindMed) Inc. (MNMD) have performed compared to their sector so far this year.

2 months ago · seekingalpha.com

Anixa Biosciences: Oncology Platform With Asymmetric Upside

ANIX has a dual-platform approach. It has an FSHR‑targeted CAR‑T program for ovarian cancer and an α‑lactalbumin breast cancer vaccine. Their Phase 1 CAR‑T showed reasonable safety, as one patient rem...